The management of skin toxicity during cetuximab treatment in advanced colorectal cancer: How much does it cost? A retrospecive economic assessment from a single-center experience

Tumori

Volumn 98, Issue 4, 2012, Pages 408-412

  Giuliani, Jacopo ^a   Indelli, Monica ^a   Marzola, Marina ^a   Raisi, Elena ^a   Frassoldati, Antonio ^a  

^a UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Cetuximab; Colorectal cancer; Economic; Skin toxicity

Indexed keywords

CETUXIMAB;

ADVANCED CANCER; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; ECONOMIC EVALUATION; HEALTH CARE COST; HOSPITALIZATION COST; HUMAN; OVERALL SURVIVAL; PATIENT CARE; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; SKIN TOXICITY;

EID: 84867210239     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161209800402     Document Type: Article

References (22)

1. Li T, Perez-Soler R: Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol, 4: 107-119, 2009.
2. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med, 351: 337-345, 2004. (Pubitemid 38944402)
3. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med, 360: 1408-1417, 2009.
4. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med, 359: 1757-1765, 2008.
5. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med; 354: 567-578, 2006. (Pubitemid 43209104)
6. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol, 11: 21-28, 2010.
7. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med, 359: 1116-1127, 2008.
8. Orditura M, De Vita F, Galizia G, Lieto E, Vecchione L, Vitiello F, Martinelli E, Ciardiello F: Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis. Oncol Rep, 21: 1023-1028, 2009.
9. Rodríguez-Murphy E, Villanueva-Herraiz S, Ortega-García MP, Pérez-Feliu A, López-Montenegro Soria MA, Camps-Herrero C: Cutaneous toxicity associated with cetuximab treatment in metastatic colorectal cancer. Farm Hosp, 35: 114-120, 2011.
10. Racca P, Fanchini L, Caliendo V, Ritorto G, Evangelista W, Volpatto R, Milanesi E, Ciorba A, Paris M, Facilissimo I, Macripò G, Clerico M, Ciuffreda L: Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic/dermatologic cooperation. Clin Colorectal Cancer, 7: 48-54, 2008. (Pubitemid 351252451)
11. National Cancer Institute Common Terminology Criteria for Adverse Events, v3.0; http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc. htm
12. Wollenberg A, Moosmann N, Klein E, Katzer K: A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition. Exp Dermatol, 17: 790-792, 2008.
13. Romito F, Giuliani F, Cormio C, Tulipani C, Mattioli V, Colucci G: Psychological effects of cetuximab-induced cutaneous rash in advanced colorectal cancer patients. Support Care Cancer, 18: 329-334, 2010.
14. Segaert S, Tabernero J, Chosidow O, Dirschka T, Elsner J, Mancini L, Maughan T, Morere JF, Santoro A, Sobrero A, Van Cutsem E, Layton A: The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges, 3: 599-606, 2005. (Pubitemid 41647826)
15. Duffour J, Thézenas S, Dereure O, Garcin A, Caron J, Samalin E, Portales F, Fiess C, Chalbos P, Gestin-Boyer C, Ychou M, Guillot B: Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: a pilot comparative study. Eur J Cancer; 46: 3169-3174, 2010.
16. Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M: Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol, 16: 16-26, 2009.
17. Pinto C, Barone CA, Girolomoni G, Russi EG, Merlano MC, Ferrari D, Maiello E; American Society of Clinical Oncology; European Society of Medical Oncology: Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist, 16: 228-238, 2011.
18. Brown B, Diamantopoulos A, Bernier J, Schöffski P, Hieke K, Mantovani L, Launois R, Griebsch I, Robinson P: An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. Value Health, 11: 791-799, 2010.
19. Ocvirk J, Rebersek M: Management of cutaneous side effects of cetuximab therapy with vitamin K1 crème. Radiol Oncol, 42: 215-224, 2008.
20. Tsutani K, Igarashi A, Shiroiwa T: Pharmacoeconomics of molecular target drugs in Japan. Nihon Rinsho, 68: 1923-1928, 2010.
21. Pander J, Gelderblom H, Antonini NF, Tol J, van Krieken JH, van der Straaten T, Punt CJ, Guchelaar HJ: Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur J Cancer; 46: 1829-1834, 2010.
22. Aiello M, Vella N, Cannavò C, Scalisi A, Spandidos DA, Toffoli G, Buonadonna A, Libra M, Stivala F: Role of genetic polymorphisms and mutations in colorectal cancer therapy (review). Mol Med Report, 4: 203-208, 2011.